Pitch directly to Pharma: Pharmacovigilance and Safety Signal Detection solutions.
FREE Online Pitch Event from R2GConnect. Learn more and apply here:
Digital Health Solutions for Pharmacovigilance and Safety Signal Detection
For this online pitch event, R2GConnect will select a group of Pharmacovigilance and Safety Signal Detection teams to pitch directly to pharma partners (AstraZeneca, Sanofi, Pfizer, and others) on June 30.
The deadline to be considered is June 23.
If you'd like a slot, you can sign up here: https://www.r2gconnect.com/briefing-details?recordId=recBjb2ICzyvC8cut&ref=Sa&type=brief
Partnership Opportunity Description
Pharmacovigilance (PV) — the science of monitoring and improving the safety of medicines — is a core responsibility for every pharmaceutical company. Its purpose is to detect, assess, and prevent adverse effects or any other drug-related problems throughout a product’s lifecycle.
A key element of PV is safety signal detection, which involves identifying potential new relationships or changes in known relationships between a drug and reported adverse events. Traditional pharmacovigilance systems often rely on manual processes and retrospective analyses, making it difficult to detect safety signals quickly.
With the rise of digital health tools, pharma now has the opportunity to make pharmacovigilance real-time, data-driven, and more predictive.
Challenge
Pharmaceutical companies are looking for digital health vendors that can help modernize their pharmacovigilance operations by:
Capturing and integrating real-world data from multiple sources.
Detecting and analyzing potential safety signals early.
Automating case processing, reporting, and compliance workflows.
Engaging patients directly in adverse event reporting and follow-up.
The challenge is to transition from manual, fragmented systems to scalable, digital, and data-driven pharmacovigilance models.
What We Are Looking For
The open call is aimed at innovative healthtech companies developing scalable digital solutions that improve pharmacovigilance, drug safety, and post-market surveillance.
Relevant applicants may include:
=> AI-driven pharmacovigilance software providers
=> Adverse event intake and automation platforms
=> Signal detection and safety analytics companies
=> NLP and LLM providers specialized in medical or regulatory workflows
=> Real-world evidence and data integration platforms
=> Clinical safety and risk management technology companies
=> Regulatory intelligence and compliance automation providers
=> Social media and patient-generated safety monitoring solutions
=> Workflow orchestration and reporting automation vendors
=> Digital biomarker and connected device safety monitoring companies
=> Safety-focused interoperability and data infrastructure providers
The open call is particularly relevant for startups and scaleups offering:
=> SaaS-based platforms
=> AI-enabled workflow automation
=> Interoperable safety ecosystems
=> Real-time safety intelligence
=> GxP-compliant infrastructure
=> Global regulatory readiness
Solutions should demonstrate measurable value in operational efficiency, signal quality, compliance, scalability, or patient safety outcomes.
Collaboration Model
Vendors should be able to provide their typical commercial offer (licensing, SaaS, or service-based).
Selected companies will have the opportunity to pitch their solution in front of pharmaceutical companies.
Promising vendors may be directly invited for 1:1 calls by interested pharma partners.
Collaboration formats may include paid pilot projects, vendor partnerships, or platform integrations.
Desired Outcome
a) The goal is to identify digital health companies capable of:
b) Improving pharmacovigilance efficiency and compliance.
c) Reducing time to detect and respond to safety signals.
d) Supporting continuous, real-time safety monitoring.
e) Enabling scalable deployment across global pharma operations.